Slingshot members are tracking this event:
Top-line data from the Open label Phase 2 trial comparing ridinilazole to fidaxomicin is expected to be reported in Q2 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Oct 09, 2017
Related Keywords Phase 2 Open-label Extention Study, C Difficile, Ridinilazole, Fidaxomicin, Dificid, Gut Microbiome